Conversely, patients with high SPEF2 expression and a high tumor mutational burden exhibited shorter OS (p=0.0023, Hazard ratio [HR]: 2.17, 95% CI: 1.3 – 3.62), (data not shown). This evidence concerns the gene SPEF2 and neoplasm.